CABA - Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
2024-06-28 13:42:28 ET
Summary
- Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies.
- It's stock price rose >$25 due to positive data produced by a drug with the same MoA as CABA-201, showing remarkable results with many patients experiencing full recoveries.
- Cabaletta stock has been sinking in 2024 however due to slow progress, manufacturing concerns, and disappointing recent data release.
- Cabaletta plans to continue studies on CABA-201 for various autoimmune conditions, with the next data update due before the end of the year.
- The next data readout feels crucial - signs of efficacy will be greeted with a surge in share price value, but poor results could drive it back into delisting territory. There is all to play for.
Investment Overview - Cabaletta's Miraculous Recovery On Potential Best-In-Class Autoimmune Cell Therapy
I last covered Cabaletta Bio, Inc. ( CABA ) in a note for Seeking Alpha in September last year, giving the Philadelphia-based biotech's stock a "buy" rating. In that note, I provided an overview of the company's progress since its IPO in 2019, which raised ~$75m at $11 per share....
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment